search

Active clinical trials for "Carcinoma, Ovarian Epithelial"

Results 1671-1680 of 1704

Prospective Identification and Validation of "BRCANess" Profile in Ovarian Epithelial Cancer

Ovarian Neoplasms

This is an observational prospective study. Patients diagnosed with advanced epithelial ovarian cancer (stage IC or higher) since 2008 will be asked to participate in this study by signing an informed consent. Tumour samples will be reviewed to confirm the diagnosis and to select the best regions for tissue sampling to perform the following molecular studies: array-based Comparative Genomic Hybridization and Next Generation Sequencing. Detected mutations will be analysed by Sanger sequencing. FISH probes will be designed and tested on the samples.

Unknown status2 enrollment criteria

Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian...

Fallopian Tube CancerOvarian Cancer1 more

RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment. PURPOSE: This research study is looking at biomarkers in predicting response in patients with advanced ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.

Unknown status10 enrollment criteria

Perioperative Assessment of Right Ventricular Function and Venous Return in Patients With Epithelial...

Right Ventricular Function and Venous Return

In this prospective, observational study the investigators assess the perioperative course of right ventricular function in combination with the venous return in patients undergoing major non-cardiac surgery. The study aims to investigate if patients undergoing major non-cardiac surgery develop an impairment of right ventricular function and/or venous return. Furthermore, the study evaluates if an impairment of right ventricular function and/or venous return is associated to left ventricular function, arterial side of the circulation and to postoperative clinical outcome.

Withdrawn28 enrollment criteria

Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC)

Endometrioid CarcinomaClear Cell Carcinoma1 more

The purpose of this study is to determine whether a relationship exists between a previously established diagnosis of endometriosis and the consecutive risk of developing a clear cell or endometrioid ovarian carcinoma. All histopathological records since 1980 with these diagnoses (endometriosis, clear cell and endometrioid ovarian carcinoma) will be reviewed. Cancer registry data will be assessed to investigate differences in survival of women with endometriosis-associated ovarian carcinomas and those ovarian carcinoma patients without previous diagnosis of endometriosis.

Withdrawn7 enrollment criteria

Research Study in Patients With Advanced Ovarian Epithelial Cancer

Ovarian Serous CystadenocarcinomaOvarian Serous Surface Papillary Adenocarcinoma4 more

This research trial studies tissue samples from patients with ovarian cancer in the laboratory. Analyzing tissue samples from patients in the laboratory may help doctors learn more about cancer.

Withdrawn8 enrollment criteria

Tazemetostat Expanded Access Program for Adults With Solid Tumors

Epithelioid Sarcoma (Ex-US Only)Spindle Cell Sarcoma18 more

Patients with a diagnosis listed under "conditions" below are eligible to be considered for the EAP. These conditions must be serious or life-threatening at the time of enrollment and appropriate, comparable, or satisfactory alternative treatments must have been tried without clinical success. Patients with conditions not listed under "conditions" below are not eligible for the tazemetostat EAP.

No longer available22 enrollment criteria

A Genomic Analysis of Evolution of Epithelia Ovarian Tumors

Epithelial Ovarian CancerEpithelial Ovarian Tumor of Borderline Malignancy2 more

Epithelial ovarian carcinomatous and borderline components sometimes appeared in one patient. This study aims to analyze the genomic patterns of the carcinomatous and borderline components in the ovarian epithelial tissues. These tissues will be collected from paraffin section by microdissection to distinguish normal, carcinomatous and borderline tissues.

Unknown status4 enrollment criteria

Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer

Epithelial Ovarian CancerChinese4 more

The homologous recombination deficiency (HRD) status in Chinese population with epithelial ovarian cancer (EOC) is little known. This study would recruit 1300 Chinese EOC patients. A multi-panel testing of 36 genes would be given for these patients in their peripheral blood and tumor tissues. These 36 genes include: BRCA1, BRCA2, ABRAXAS1(FAM175A), ATM, ATR, BAP1, BARD1, BRIP1, C11ORF30(EMSY), CDK12, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCI, FANCL, MRE11A, NBN, PALB2, PPP2R2A, PTEN, RAD50, RAD51B, RAD51C, RAD51D, RAD54B, RAD54, MLH1, MSH2, MSH6, PMS2, EPCAM, STK11, TP53, CDH1. The study would select 150 patients with pathogenic or likely pathogenic mutations in BRCA1/2 and 150 patients without these mutations to further explore the HRD status. The HRD model is based on the loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST). The mutated genes, HRD score model and their relationship with the prognosis, would provide a full description of for the Chinese EOC patients.

Unknown status5 enrollment criteria

Imaging Study in Advanced Ovarian Cancer

Ovarian Cancer

The aim of the study is the assessment of tumour sites critical for the achievement of optimal cytoreduction in patients with advanced ovarian cancer using Ultrasound, CT and WB-DWI/MRI. The study uses an equivalence design with a hypothesis that cases with non-resectable disease identified by Index test (Ultrasound, CT and WB-DWI MRI) are equivalent to a portion of cases identified during surgery.

Unknown status12 enrollment criteria

Dual PETOvac - Dual Time PET/CT in the Preoperative Assessment of Ovarian Cancer

Ovarian Cancer

The investigators want to compare the use of MRI with PET/CT preformed after 1 hour and 3 hours in preoperative assessment of resectability. The investigators' hypothesis is that dual time PET/CT performed at 60 and 180 minutes will increase the diagnostic accuracy of conventional PET (performed at 60 minutes) in preoperative assessment of resectability. Further more the investigators suggest that the GLUT/G6Pase index correlates to the SUVmax. And retention index (RI, see Methods - PET protocol) is a prognostic marker in ovarian cancer.

Unknown status6 enrollment criteria
1...167168169...171

Need Help? Contact our team!


We'll reach out to this number within 24 hrs